Open AccessReview
Neuropathic Pain Treatment: Still a Challenge
by
Osvaldo J.M. Nascimento, Bruno L. Pessoa, Marco Orsini, Pedro Ribeiro, Eduardo Davidovich, Camila Pupe, Pedro Moreira Filho, Ricardo Menezes Dornas, Lucas Masiero, Juliana Bittencourt and Victor Hugo Bastos
Cited by 17 | Viewed by 514
Abstract
Neuropathic pain (NP) is the result of a series of conditions caused by diseases or lesions to the somatosensory system. Due to the better understanding of NP pathophysiology previously unexplored therapies have been used with encouraging results. In this group, acetyl-L-carnitine, alpha-lipoic-acid, cannabinoids,
[...] Read more.
Neuropathic pain (NP) is the result of a series of conditions caused by diseases or lesions to the somatosensory system. Due to the better understanding of NP pathophysiology previously unexplored therapies have been used with encouraging results. In this group, acetyl-L-carnitine, alpha-lipoic-acid, cannabinoids, clonidine, EMA401, botulinum toxin type A and new voltage-gated sodium channel blockers, can be included. Besides, changing paradigms may occur with the advent of optogenetics and a better understanding of epigenetic regulation. We reviewed the published literature on the pharmacological treatment of NP. Despite the interesting results, randomized controlled trials are demanded the majority of the therapies previously mentioned. In spite of several studies for the relief of NP, pain control continues being a challenge.
Full article